Trial Profile
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Sacituzumab govitecan (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- 25 May 2023 Planned initiation date changed from 18 May 2023 to 25 May 2023.
- 25 May 2023 Status changed from not yet recruiting to recruiting.
- 03 May 2023 Status changed from planning to not yet recruiting.